All In Biotech

Drug Trial Radar · NCT05150587

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

A Phase IIa, Multicenter, Double Blind, Placebo Controlled, Randomized Clinical Trial to Assess Safety, Efficacy and Pharmacokinetics of Rifaximin Delayed-Release (Rifaximin-EIR) in Patients With Moderate-to-severe Papulopustular Rosacea

Last checked: Nov 20, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

216

Actual

Start

Oct 5, 2021

Primary completion

Oct 20, 2022

Study completion Oct 20, 2022

Sponsor

Lead sponsor
Alfasigma S.p.A.Industry
Sponsor type
Industry
Collaborators
bioRASI, LLC
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT). The objective of this study is twofold: 1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea. 2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.

Conditions

  • Papulopustular Rosacea

Interventions

  • RifaximinDrug

    Rifaximin tablets

  • PlaceboDrug

    Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory LesionsTime frame: 30 days
  2. Co-primary Endpoint: Treatment Success RateTime frame: 30 days

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Research Ventures

    Yuma, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • Long Beach Clinical Trials

    Long Beach, California

  • Metropolis Dermatology

    Los Angeles, California

  • LA Universal Research Center

    Los Angeles, California

  • Cosmetic Laser Dermatology

    San Diego, California

  • UCSD

    San Diego, California

  • University Clinical Trials, Inc.

    San Diego, California

  • Skin Care Research

    Boca Raton, Florida

  • MOORE Clinical Research,Inc.

    Brandon, Florida

  • Sweet Hope Research Specialty, Inc.

    Hialeah, Florida

  • Savin Medical Group

    Miami Lakes, Florida

  • Leavitt Medical Associates of Florida

    Ormond Beach, Florida

  • DelRicht Research

    Marietta, Georgia

  • DS Research

    Clarksville, Indiana

  • Skin Science PLLC

    Louisville, Kentucky

  • DS Research

    Louisville, Kentucky

  • Delricht Research Baton Rouge LA

    Baton Rouge, Louisiana

  • Delricht Research Covington LA

    Covington, Louisiana

  • DelRicht Research Houma Louisiana

    Houma, Louisiana

  • DelRicht Research

    New Orleans, Louisiana

  • Revival Research Institute, LLC.

    Troy, Michigan

  • Grekin Skin Care Institute

    Wyandotte, Michigan

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • JDR Dermatology Research

    Las Vegas, Nevada

  • JUVA Skin and Laser Center

    New York, New York

  • Onsite Clinical Solutions

    Charlotte, North Carolina

  • Dermatology Consulting Services, PLLC

    High Point, North Carolina

  • DelRicht Research

    Tulsa, Oklahoma

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Paddington Testing Co, Inc

    Philadelphia, Pennsylvania

  • Dermatology Treatment and Research Center

    Dallas, Texas

  • 3A Research

    El Paso, Texas

  • DelRicht Research Frisco Texas

    Frisco, Texas

  • Austin Institute for Clinical Research

    Pflugerville, Texas

  • Progressive Clinical Research

    San Antonio, Texas

  • Velocity Clinical Research

    Salt Lake City, Utah

  • West End Dermatology Associates

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.